Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dixiechick who wrote (8351)	11/26/2009 12:23:48 PM
From: li3511	Read Replies (1) of 63289

> material non public information I'm confused. What do you consider "material" and "non public?" Anecdotal stories of how two or three patients are doing in a clinical trial? That they post on the Internet? I think there's a difference between "material" and "statistically insignificant." Rather than gaining great insight, Idaho may be deluding himself into thinking hPAM4 is better than it really is. That's the usual effect when you selectively concentrate on a couple of random "winners" while your mind filters out the rest of the population. No one will know of Idaho's "material" information has any value until several months from now. We've seen this before in epratuzumab development for both NHL and SLE, as well as most drugs in early development. One or two great "successes" are held up as exemplars, which later turn out to be data points way out on the Bell curve.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next